Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Dermatitis : Contact, Atopic, Occupational, Drug|November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical TrialsJonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
American Journal of Clinical Dermatology|December 12, 2019
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical TrialAmy S Paller, Ashish Bansal, Eric L Simpson, et al.
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology|September 9, 2018
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisEmma Guttman-Yassky, Robert Bissonnette, Benjamin Ungar, et al.
The New England Journal of Medicine|May 22, 2018
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaKlaus F Rabe, Parameswaran Nair, Guy Brusselle, et al.
Lancet (London, England)|October 12, 2015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Eric L Simpson, Lisa A Beck, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 16, 2021
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic DermatitisMark Boguniewicz, Lisa A Beck, Lawrence Sher, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 8, 2022
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory DiseasesG Walter Canonica, Arnaud Bourdin, Anju T Peters, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 16, 2019
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaJonathan Corren, Mario Castro, Thomas O'Riordan, et al.
Pageof 8